C4 Therapeutics, Inc. (CCCC) Earnings History
Annual and quarterly earnings data from 2018 to 2025
Loading earnings history...
CCCC EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CCCC Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 77.8% | -290.7% | -292.1% |
| 2024 | 100.0% | -336.1% | -296.0% |
| 2023 | 62.7% | -669.8% | -638.3% |
| 2022 | 100.0% | -416.6% | -412.2% |
| 2021 | 100.0% | -179.4% | -183.2% |
Download Data
Export CCCC earnings history in CSV or JSON format
Free sign-in required to download data
C4 Therapeutics, Inc. (CCCC) Earnings Overview
As of May 8, 2026, C4 Therapeutics, Inc. (CCCC) reported trailing twelve-month net income of -$105M, reflecting +16.4% year-over-year growth. The company earned $-1.27 per diluted share over the past four quarters, with a net profit margin of -292.1%.
Looking at the long-term picture, CCCC's historical earnings data spans multiple years. The company achieved its highest annual net income of -$16M in fiscal 2018.
C4 Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ARVN (-$81M net income, -30.8% margin), KYMR (-$315M net income, -794.4% margin), PRAX (-$327M net income), CCCC has room to improve margins relative to the peer group. Compare CCCC vs ARVN →
CCCC Earnings vs Peers
Earnings metrics vs comparable public companies
CCCC Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$105M | +0.3% | -$104M | $-1.27 | -292.1% | -290.7% |
| 2024 | -$105M | +20.5% | -$120M | $-1.52 | -296.0% | -336.1% |
| 2023 | -$132M | -3.4% | -$139M | $-2.67 | -638.3% | -669.8% |
| 2022 | -$128M | -52.8% | -$130M | $-2.62 | -412.2% | -416.6% |
| 2021 | -$84M | -26.5% | -$82M | $-1.82 | -183.2% | -179.4% |
| 2020 | -$66M | -94.5% | -$60M | $-1.54 | -199.8% | -182.1% |
| 2019 | -$34M | -117.0% | -$35M | $-0.79 | -159.5% | -165.8% |
| 2018 | -$16M | - | -$16M | $-1.06 | -81.1% | -84.6% |
See CCCC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CCCC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CCCC vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCCCC — Frequently Asked Questions
Quick answers to the most common questions about buying CCCC stock.
Is CCCC growing earnings?
CCCC EPS is $-1.27, with earnings growth accelerating to +16.4%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-105M.
What are CCCC's profit margins?
C4 Therapeutics, Inc. net margin is -292.1%, with operating margin at -290.7%. Below-average margins reflect competitive or cost pressures.
How consistent are CCCC's earnings?
CCCC earnings data spans 2018-2025. The accelerating earnings trend is +16.4% YoY. Historical data enables comparison across business cycles.